SciSparc

IBI-Ag is a biotechnology firm that specializes in creating innovative bioinsecticides. Their primary focus is on finding and creating environmentally friendly solutions for insect control using cutting-edge technology. By utilizing advanced methods, IBI-Ag produces effective and safe bio-insect control products that are also cost-efficient for farmers due to their fermentation capabilities.

Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.

Minovia is a biotechnology research firm that specializes in developing treatments for mitochondrial disease. They utilize their Mitochondrial Augmentation Therapy (MAT) platform, which involves using cell therapy to repair damaged mitochondrial DNA. Founded in 2011, Minovia is located in Tirat Carmel, Hefa, Israel.

Neurolief is focused on providing relief to patients with mental health and neurological disorders through innovative neuromodulation technology. The company is made up of experts in neuroscience and neurotech, and they have created a groundbreaking non-invasive brain neuromodulation system that can target multiple neural pathways simultaneously to impact mood and pain regulation.

NurExone Biologic is creating a drug platform using biological exosomes to repair damage in the Central Nerve System.

Phytolon is transforming the process of creating food colors by using an innovative and environmentally friendly technology. This allows them to produce top-notch, healthy food colors at an affordable price. Phytolon's goal is to utilize scientific progress to improve human health while also ensuring sustainability for the environment.

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Kadimastem is a company that focuses on developing and commercializing stem cell-based treatments for diabetes and neurodegenerative disorders. Their technology allows them to differentiate stem cells into insulin-producing beta cells and various neural cells. They are currently working on therapeutic programs for diabetes and ALS, using differentiated stem cells to potentially implant into patients. The company partners with pharmaceutical companies to screen potential drug compounds on their stem cell-derived cells in order to develop safe drugs. Kadimastem is located in Nes Ziona, Israel.

Restore Medical creates and offers a device-oriented treatment for congestive heart failure that enhances patient well-being and lowers hospital re-admission rates. Their innovative product, ContraBand, is a catheter-delivered implant placed in the pulmonary arteries to assist in treating left ventricle failure in patients with preserved right ventricle function. Established in 2016, Restore Medical is based in Or Yehuda, Israel.

Brevel has created an innovative method of cultivating microalgae that is both sustainable and cost-effective, while also producing high-quality output for a range of markets that have yet to be explored. This technology utilizes advanced indoor systems that are sterile and fully automated, with intense internal illumination. As a result, Brevel has achieved remarkable results, including a cost reduction of over 90% and yields that are up to 200 times higher than existing alternatives. Leveraging these production capabilities, Brevel is now venturing into various markets that require products derived from microalgae.

In order to target and eliminate bacteria that harm the skin's look as well as dangerous bacteria in chronic conditions such cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer, BiomX is developing both natural and manufactured phage cocktails. In order to attack specific bacterial targets, BiomX develops and certifies its own phage compositions.

Lutris Pharma creates medications that enhance the efficiency of anti-cancer treatments. One of their products, LUT014, is a topical B-Raf inhibitor that helps patients receive EGFR inhibitors without experiencing common skin-related side effects. Founded in 2015, Lutris Pharma is located in Tel Aviv-yafo, Israel.